BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,710,595 | +46.0% | 64,869 | -5.1% | 0.00% | +33.3% |
Q2 2023 | $1,171,891 | +16.2% | 68,350 | +12.3% | 0.00% | +50.0% |
Q1 2023 | $1,008,926 | +179.2% | 60,852 | +28.3% | 0.00% | +100.0% |
Q4 2022 | $361,386 | -23.3% | 47,426 | +0.2% | 0.00% | 0.0% |
Q3 2022 | $471,000 | +52.9% | 47,343 | +39.3% | 0.00% | 0.0% |
Q2 2022 | $308,000 | +8.1% | 33,980 | +458.4% | 0.00% | 0.0% |
Q3 2021 | $285,000 | – | 6,085 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |